The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

NSDUH only queried opioid misusers about opioid use disorder symptoms. After they changed the protocol and asked all ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries ...

A recent study highlights the effectiveness of Pain Coping Skills Training (PCST) in reducing chronic pain among dialysis patients. The study, involving 643 participants, shows how non-opioid ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

All three cannabinoids reduced the electrical activity linked to Nav1.8, but CBG had the strongest effect. This suggests that CBG could be the most promising candidate for developing new pain ...

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.